This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Miller, K. D. Articles by Sledge, G. W. Search for Related Content PubMed PubMed Citation Articles by Miller, K. D. Articles by Sledge, G. W., Jr Social Bookmarking                            What's this?

Combination Versus Sequential Doxorubicin and Docetaxel as Primary Chemotherapy for Breast Cancer: A Randomized Pilot Trial of the Hoosier Oncology Group

From the Hoosier Oncology Group and the Walther Cancer Institute, Indianapolis, IN.

Address reprint requests to Kathy D. Miller, MD, 3202 N Meridian St, Indianapolis, IN 46202-4646; email kathmill{at}iupui.edu

PURPOSE: To evaluate the efficacy and toxicity of combination and sequential dose-dense chemotherapy with doxorubicin and docetaxel (Taxotere; Rhône-Poulenc Rorer, Collegeville, PA) as primary chemotherapy of breast cancer.

PATIENTS AND METHODS: Patients with newly diagnosed stage II or noninflammatory stage III breast cancer were randomly assigned to receive the same total doses of doxorubicin and docetaxel over a 12-week period before definitive surgery. Patients in arm A received sequential therapy with doxorubicin 75 mg/m² every 2 weeks for three cycles followed by docetaxel 100 mg/m² every 2 weeks for three cycles. Patients in arm B received combination therapy with doxorubicin 56 mg/m² plus docetaxel 75 mg/m² every 3 weeks for four cycles. Granulocyte colony-stimulating factor was administered on days 2 to 12 of each cycle in both groups.

RESULTS: Forty patients were entered onto the trial. Pretreatment tumor size averaged 5.7 cm with clinicallypositive axillary lymph nodes in 23 patients (57%). As expected, myelosuppression was severe in both groups; however, 80% of planned dose-intensity was delivered. Hand-foot syndrome was more common after sequential therapy. Clinical responses were similar in both groups, with an overall response rate of 87%, including 20% clinical complete remissions. Pathologic complete remission or residual in situ disease only was confirmed in five patients (12.8%). Patients who received sequential therapy had fewer positive lymph nodes (mean, 2.17 v 4.81; P < .037) at definitive surgery.

CONCLUSION: Primary chemotherapy with doxorubicin and docetaxel is well tolerated and highly active. A sequential treatment schedule increases toxicity but may result in more substantial lymph node clearance than combination therapy.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				S. Puhalla, E. Mrozek, D. Young, S. Ottman, A. McVey, K. Kendra, N. J. Merriman, M. Knapp, T. Patel, M. E. Thompson, et al. Randomized Phase II Adjuvant Trial of Dose-Dense Docetaxel Before or After Doxorubicin Plus Cyclophosphamide in Axillary Node-Positive Breast Cancer J. Clin. Oncol., April 1, 2008; 26(10): 1691 - 1697. [Abstract] [Full Text] [PDF]

				C Natoli, E Cianchetti, N Tinari, D Angelucci, A Grassadonia, M Zilli, C Ficorella, E Ricevuto, S Grossi, M De Tursi, et al. A phase II study of dose-dense epirubicin plus cyclophosphamide followed by docetaxel plus capecitabine and pegfilgrastim support as preoperative therapy for patients with stage II, IIIA breast cancer Ann. Onc., June 1, 2007; 18(6): 1015 - 1020. [Abstract] [Full Text] [PDF]

				P Piedbois, D Serin, F Priou, P Laplaige, S Greget, E Angellier, E Teissier, J-F Berdah, M Fabbro, B Valenza, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: docetaxel followed by epirubicin/cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study Ann. Onc., January 1, 2007; 18(1): 52 - 57. [Abstract] [Full Text] [PDF]

				W. J. Gradishar, S. B. Wedam, M. Jahanzeb, J. Erban, S. A. Limentani, K.-T. Tsai, S. R. Olsen, and S. M. Swain Neoadjuvant docetaxel followed by adjuvant doxorubicin and cyclophosphamide in patients with stage III breast cancer Ann. Onc., August 1, 2005; 16(8): 1297 - 1304. [Abstract] [Full Text] [PDF]

				T.R. J. Evans, A. Yellowlees, E. Foster, H. Earl, D. A. Cameron, A. W. Hutcheon, R. E. Coleman, T. Perren, C. J. Gallagher, M. Quigley, et al. Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study J. Clin. Oncol., May 1, 2005; 23(13): 2988 - 2995. [Abstract] [Full Text] [PDF]

				A. Hamilton and G. Hortobagyi Chemotherapy: What Progress in the Last 5 Years? J. Clin. Oncol., March 10, 2005; 23(8): 1760 - 1775. [Full Text] [PDF]

				J. Schwartz, S. M. Domchek, W.-T. Hwang, and K. Fox Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer Ann. Onc., February 1, 2005; 16(2): 247 - 252. [Abstract] [Full Text] [PDF]

				M. S. Mano and A. Awada Primary chemotherapy for breast cancer: the evidence and the future Ann. Onc., August 1, 2004; 15(8): 1161 - 1171. [Abstract] [Full Text] [PDF]

				E. Alba, M. Martin, M. Ramos, E. Adrover, A. Balil, C. Jara, A. Barnadas, A. Fernandez-Aramburo, P. Sanchez-Rovira, M. Amenedo, et al. Multicenter Randomized Trial Comparing Sequential With Concomitant Administration of Doxorubicin and Docetaxel As First-Line Treatment of Metastatic Breast Cancer: A Spanish Breast Cancer Research Group (GEICAM-9903) Phase III Study J. Clin. Oncol., July 1, 2004; 22(13): 2587 - 2593. [Abstract] [Full Text] [PDF]

				L. G. Estevez and W. J. Gradishar Evidence-Based Use of Neoadjuvant Taxane in Operable and Inoperable Breast Cancer Clin. Cancer Res., May 15, 2004; 10(10): 3249 - 3261. [Abstract] [Full Text] [PDF]

				S. Cresta, G. Grasselli, M. Mansutti, A. Martoni, G. Lelli, G. Capri, F. Buzzi, G. Robustelli Della Cuna, A. Jirillo, E. Terzoli, et al. A randomized phase II study of combination, alternating and sequential regimens of doxorubicin and docetaxel as first-line chemotherapy for women with metastatic breast cancer Ann. Onc., March 1, 2004; 15(3): 433 - 439. [Abstract] [Full Text] [PDF]

				G. W. Sledge Jr Preoperative Chemotherapy for Breast Cancer: Lessons Learned and Future Prospects J. Clin. Oncol., December 15, 2003; 21(24): 4481 - 4482. [Full Text] [PDF]

				P. Gilbar Palmar-plantar erythrodysesthesia Journal of Oncology Pharmacy Practice, December 1, 2003; 9(4): 137 - 150. [Abstract] [PDF]

				H. D. Bear, S. Anderson, A. Brown, R. Smith, E. P. Mamounas, B. Fisher, R. Margolese, H. Theoret, A. Soran, D. L. Wickerham, et al. The Effect on Tumor Response of Adding Sequential Preoperative Docetaxel to Preoperative Doxorubicin and Cyclophosphamide: Preliminary Results From National Surgical Adjuvant Breast and Bowel Project Protocol B-27 J. Clin. Oncol., November 15, 2003; 21(22): 4165 - 4174. [Abstract] [Full Text] [PDF]

				G. Ganem, M. Tubiana-Hulin, P. Fumoleau, M. Combe, J.-L. Misset, J.-M. Vannetzel, T. Bachelot, L. R. De Ybarlucea, V. Lotz, B. Bendahmane, et al. Phase II trial combining docetaxel and doxorubicin as neoadjuvant chemotherapy in patients with operable breast cancer Ann. Onc., November 1, 2003; 14(11): 1623 - 1628. [Abstract] [Full Text] [PDF]

				H. Gogas and G. Fountzilas The role of taxanes as a component of neoadjuvant chemotherapy for breast cancer Ann. Onc., May 1, 2003; 14(5): 667 - 674. [Full Text] [PDF]

				L. G. Estevez, J. M. Cuevas, A. Anton, J. Florian, J. M. Lopez-Vega, A. Velasco, F. Lobo, A. Herrero, and J. Fortes Weekly Docetaxel as Neoadjuvant Chemotherapy for Stage II and III Breast Cancer: Efficacy and Correlation with Biological Markers in a Phase II, Multicenter Study Clin. Cancer Res., February 1, 2003; 9(2): 686 - 692. [Abstract] [Full Text] [PDF]

				I. C. Smith, S. D. Heys, A. W. Hutcheon, I. D. Miller, S. Payne, F. J. Gilbert, A. K. Ah-See, O. Eremin, L. G. Walker, T. K. Sarkar, et al. Neoadjuvant Chemotherapy in Breast Cancer: Significantly Enhanced Response With Docetaxel J. Clin. Oncol., March 15, 2002; 20(6): 1456 - 1466. [Abstract] [Full Text] [PDF]

				M. S. Aapro Adjuvant Therapy of Primary Breast Cancer: A Review of Key Findings from the 7th International Conference, St. Gallen, February 2001 Oncologist, August 1, 2001; 6(4): 376 - 385. [Abstract] [Full Text] [PDF]

				M. S. Aapro Neoadjuvant Therapy in Breast Cancer: Can We Define Its Role? Oncologist, June 1, 2001; 6(2008): 36 - 39. [Abstract] [Full Text] [PDF]

				G. Fountzilas, C. Papadimitriou, U. Dafni, D. Bafaloukos, D. Skarlos, L. A. Moulopoulos, E. Razis, H. P. Kalofonos, G. Aravantinos, E. Briassoulis, et al. Dose-Dense Sequential Chemotherapy With Epirubicin and Paclitaxel Versus the Combination, as First-Line Chemotherapy, in Advanced Breast Cancer: A Randomized Study Conducted by the Hellenic Cooperative Oncology Group J. Clin. Oncol., April 15, 2001; 19(8): 2232 - 2239. [Abstract] [Full Text] [PDF]